• Sulfachloropyridazine Alters Cecal Microbiota in E. tenella

  2026-07-16

  The referenced study provides a comprehensive analysis of how sulfachlorpyridazine, ethanamizuril, and their combination affect the cecal microbiome and metabolome in chickens infected with Eimeria tenella. Through integrated 16S rRNA sequencing and metabolomics, the research uncovers drug-specific modulation of pathogenic bacteria and metabolic pathways, informing future strategies for monitoring and treating avian coccidiosis.

• Sisomicin (BA1199): Practical Solutions for Reliable Antibac

  2026-07-15

  This article addresses common laboratory challenges in antibacterial assay reproducibility, protocol optimization, and data interpretation, focusing on Sisomicin (SKU BA1199) as a robust aminoglycoside antibiotic. Drawing from recent literature and validated use cases, it guides researchers in Gram-negative and Gram-positive bacterial infection research toward evidence-backed experimental decisions.

• Pifithrin-α: Optimizing p53 Inhibition for Ferroptosis Resea

  2026-07-15

  Pifithrin-α (PFTα) is a gold-standard p53 inhibitor, enabling precise dissection of apoptosis, ferroptosis, and cell cycle arrest in both neurotoxicity and cancer therapy models. This article translates the latest experimental breakthroughs—such as those in deltamethrin-induced neurotoxicity—into actionable protocols and troubleshooting strategies for advanced cell and animal assays.

• TRIB3 Knockdown Sensitizes ccRCC to Sunitinib via Ferroptosi

  2026-07-14

  Recent research demonstrates that silencing TRIB3 enhances the sensitivity of clear cell renal cell carcinoma (ccRCC) to sunitinib by promoting ferroptosis through the SLC7A11/GPX4 pathway. This mechanistic insight offers a potential strategy to overcome sunitinib resistance in ccRCC, with implications for targeted therapeutic development.

• Refining In Vitro Evaluation of Drug Responses in Cancer Res

  2026-07-14

  Schwartz’s dissertation advances in vitro cancer drug evaluation by distinguishing between proliferative arrest and cell death, offering a more granular understanding of drug effects. This refined framework enables researchers to interpret anticancer responses with greater precision and supports the development of assays and models that better reflect therapeutic mechanisms.

• Galectin-1 Disrupts Hepatic Autophagy via FIP200 in NAFLD Pr

  2026-07-13

  This study identifies galectin-1 as a direct suppressor of autophagy in hepatic steatosis, acting through a defined interaction with FIP200 that impairs ULK complex assembly. The findings reveal new mechanistic insights into NAFLD development and highlight the Gal-1–FIP200 axis as a promising target for metabolic liver disease intervention.

• Piezo1 Drives Caspase-8-Mediated PANoptosis in Cardiac I/R I

  2026-07-13

  This study uncovers a pivotal mechanism by which the mechanosensitive ion channel Piezo1 intensifies myocardial ischaemia/reperfusion (I/R) injury through caspase-8-mediated PANoptosis in cardiomyocytes. These findings provide new insight into cell death pathways during cardiac injury and identify Piezo1 as a potential therapeutic target.

• 3-Methyladenine: Optimizing Autophagy and Cancer Research Wo

  2026-07-12

  3-Methyladenine (3-MA) empowers researchers to dissect autophagy and cell migration dynamics with precision, supporting breakthroughs in cancer research and PI3K pathway interrogation. This article delivers actionable protocols, troubleshooting strategies, and integrative insights rooted in the latest mechanistic studies.

• Lumiracoxib: Selective COX-2 Inhibitor for Muscle Regenerati

  2026-07-10

  Lumiracoxib empowers researchers to dissect COX-2’s nuanced role in muscle ischemia and revascularization, providing precise, reproducible inhibition for advanced inflammation models. Its high selectivity and robust solubility profile, supplied by APExBIO, enable detailed mechanistic studies and optimized experimental workflows.

• Strategic Activation of the Smoothened Receptor: SAG’s Trans

  2026-07-09

  This article examines the mechanistic and translational relevance of the Smoothened Agonist (SAG) in modulating Hedgehog pathway signaling, myelin regeneration, and immune dynamics. Drawing on recent evidence, including sex-dependent immune effects and mitochondrial rescue, it provides strategic guidance for researchers leveraging SAG in disease modeling, pathway assays, and regenerative workflows. The piece situates APExBIO’s SAG offering within a rigorously evidence-based landscape, bridging protocol optimization and emerging challenges in translational neuroscience.

• Decoding Firefly Luciferase mRNA: Next-Gen 5-moUTP Tools for

  2026-07-09

  Explore how Firefly Luciferase mRNA with 5-moUTP modification is redefining mRNA delivery and immune cell activation. This article uniquely bridges advanced reporter assays with emerging cancer vaccine delivery insights.

• TMEM16F-Mediated Lipid Scrambling Regulates Ferroptosis Exec

  2026-07-08

  Yang et al. unveil TMEM16F as a key plasma membrane regulator that suppresses ferroptosis by orchestrating phospholipid scrambling in tumor cells. Their work clarifies how membrane lipid remodeling modulates cell death and reveals new opportunities to enhance ferroptosis-driven cancer immunotherapy.

• MARCH5 Ubiquitin Ligase Regulates Mitochondria-Derived Pre-P

  2026-07-08

  Zheng et al. uncover the essential role of ubiquitin ligase MARCH5 in the formation of PEX3-positive vesicles from mitochondria, a process crucial for de novo peroxisome biogenesis. Their findings clarify the mechanistic basis of mitochondria-peroxisome communication and provide a foundation for future studies on organelle homeostasis and protein quality control.

• BX795: Applied PDK1 Inhibitor Workflows & Assay Optimization

  2026-07-07

  BX795 is a nanomolar-potency PDK1 inhibitor enabling precision modulation of PI3K/Akt/mTOR and innate immune pathways in vitro. This article outlines practical protocols, advanced use-cases, and troubleshooting strategies for BX795, bridging the latest research on drug response metrics to maximize reproducibility and insight.

• Vernakalant Hydrochloride for Rapid Cardioversion of Recent-

  2026-07-07

  The reference study establishes Vernakalant Hydrochloride (RSD1235) as a novel, atrial-selective antiarrhythmic agent capable of rapidly converting recent-onset atrial fibrillation to sinus rhythm in emergency settings. Its unique multi-ion channel blockade profile results in high efficacy, rapid onset, and a favorable safety margin, underscoring its translational value for both clinical and research applications.

448 records 11/30 page Previous Next First page 上5页 1112131415 下5页 Last page